NASDAQ · STOCK
Dexcom
$83.46
52W $54.11 – $84.70
59/100
$32.20B
32.2
1.45
Is DXCM Bullish or Bearish?
Bullish.
Innellis AI committee rates Dexcom (DXCM) Buy with a composite score of 59/100
, based on 6 analysts with 67% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.71 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.29 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — eps growing 77.5% yoy — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- ROE of 33.8% shows genuine earnings power backing the valuation — Value
- EPS growing 77.5% YoY — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.41 means this name should amplify a favorable market regime — Macro
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
59/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 14%
of 93 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 33.8% shows genuine earnings power backing the valuation
− P/E of 34.5 is moderate-to-rich
Growth Analyst
bullish
75
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ EPS growing 77.5% YoY
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 43 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 60.7 to 59.3.
- Conviction changed from contested to moderate.
- Committee agreement increased notably from 50% to 67%.
- New bearish signals: 3 appeared.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 3 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Growth Analyst: score 78->75 (-3).
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +2 bullish signal(s).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
77.2
Overbought
MACD Histogram
0.516
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$79.63
Resistance
$88.32
Bollinger %B
1.29
Above Upper Band
Price vs Moving Averages
EMA 9
$75.86
Above
EMA 21
$74.37
Above
EMA 50
$72.25
Above
EMA 200
$70.43
Above
Fundamental Analysis
Valuation
44
Growth
74
Profitability
1
Financial Health
89
Cash Flow
37
Valuation
P/E Ratio
32.2×
P/B Ratio
12.21×
PEG Ratio
0.42
Dividend Yield
0.00%
52W High
$84.70
52W Low
$54.11
Quality & Growth
ROE
30.5%
ROA
13.2%
Gross Margin
62.8%
Operating Margin
22.9%
Revenue Growth YoY
—
Debt / Equity
0.51
AI Fundamental Assessment
P/E ratio of 32.2 (rich relative to a 15-40x range); Price-to-book of 12.2x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.3%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.6%; Current ratio of 1.73 (healthy short-term liquidity); Debt-to-equity of 0.51; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (3.66); Most recent quarter beat estimates by 1.9%; 5 consecutive earnings beats; EPS growth decelerating (+25.0% -> +0.0% QoQ); Average YoY EPS growth of 45.8%; Analyst estimates rising over recent quarters
Get the Full DXCM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →